Global Antibody-radionuclide Conjugates Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Antibody-radionuclide Conjugates market size was valued at USD 1073 million in 2022 and is forecast to a readjusted size of USD 3159.3 million by 2029 with a CAGR of 16.7% during review period.
Antibody-radionuclide Conjugates is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
The Antibody-radionuclide Conjugates Market is driven by the increasing interest in targeted cancer therapy and the potential of combining monoclonal antibodies with radioactive isotopes to deliver precise treatment. Antibody-radionuclide conjugates offer a highly focused approach to treating cancer by delivering radiation directly to tumor cells, minimizing damage to healthy tissue. As the understanding of cancer biology and immunotherapy advances, and personalized treatment options gain prominence, the demand for these conjugates continues to grow. Innovations in conjugation techniques, radiolabeling methods, and the expansion of the oncology pipeline further contribute to market expansion. However, a significant challenge for this market is the need to address complex drug development processes, optimize safety and efficacy, and navigate regulatory standards while ensuring affordability and accessibility for patients. Overcoming production challenges, minimizing off-target effects, and managing development costs are ongoing hurdles. Additionally, the market faces competition from other cancer therapies and the need for continuous research and development to enhance the efficiency and precision of antibody-radionuclide conjugates. Striking a balance between providing safe, effective, and accessible targeted cancer treatments while addressing scientific and regulatory challenges is essential for the continued growth of the Antibody-radionuclide Conjugates Market.
The Global Info Research report includes an overview of the development of the Antibody-radionuclide Conjugates industry chain, the market status of Solid Tumor (Beta-emitting, Targeted Alpha Therapy), Non Hodgkin Lymphoma (Beta-emitting, Targeted Alpha Therapy), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Antibody-radionuclide Conjugates.
Regionally, the report analyzes the Antibody-radionuclide Conjugates markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Antibody-radionuclide Conjugates market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Antibody-radionuclide Conjugates market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Antibody-radionuclide Conjugates industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Beta-emitting, Targeted Alpha Therapy).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Antibody-radionuclide Conjugates market.
Regional Analysis: The report involves examining the Antibody-radionuclide Conjugates market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Antibody-radionuclide Conjugates market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Antibody-radionuclide Conjugates:
Company Analysis: Report covers individual Antibody-radionuclide Conjugates players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Antibody-radionuclide Conjugates This may involve surveys, interviews, and analysis of consumer reviews and feedback from different ?? (Solid Tumor, Non Hodgkin Lymphoma).
Technology Analysis: Report covers specific technologies relevant to Antibody-radionuclide Conjugates. It assesses the current state, advancements, and potential future developments in Antibody-radionuclide Conjugates areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Antibody-radionuclide Conjugates market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Antibody-radionuclide Conjugates market is split by Type and ??. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and ?? in terms of value.
Market segment by Type
Chapter 1, to describe Antibody-radionuclide Conjugates product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Antibody-radionuclide Conjugates, with revenue, gross margin and global market share of Antibody-radionuclide Conjugates from 2018 to 2023.
Chapter 3, the Antibody-radionuclide Conjugates competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Antibody-radionuclide Conjugates market forecast, by regions, type and , with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Antibody-radionuclide Conjugates.
Chapter 13, to describe Antibody-radionuclide Conjugates research findings and conclusion.
Antibody-radionuclide Conjugates is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
The Antibody-radionuclide Conjugates Market is driven by the increasing interest in targeted cancer therapy and the potential of combining monoclonal antibodies with radioactive isotopes to deliver precise treatment. Antibody-radionuclide conjugates offer a highly focused approach to treating cancer by delivering radiation directly to tumor cells, minimizing damage to healthy tissue. As the understanding of cancer biology and immunotherapy advances, and personalized treatment options gain prominence, the demand for these conjugates continues to grow. Innovations in conjugation techniques, radiolabeling methods, and the expansion of the oncology pipeline further contribute to market expansion. However, a significant challenge for this market is the need to address complex drug development processes, optimize safety and efficacy, and navigate regulatory standards while ensuring affordability and accessibility for patients. Overcoming production challenges, minimizing off-target effects, and managing development costs are ongoing hurdles. Additionally, the market faces competition from other cancer therapies and the need for continuous research and development to enhance the efficiency and precision of antibody-radionuclide conjugates. Striking a balance between providing safe, effective, and accessible targeted cancer treatments while addressing scientific and regulatory challenges is essential for the continued growth of the Antibody-radionuclide Conjugates Market.
The Global Info Research report includes an overview of the development of the Antibody-radionuclide Conjugates industry chain, the market status of Solid Tumor (Beta-emitting, Targeted Alpha Therapy), Non Hodgkin Lymphoma (Beta-emitting, Targeted Alpha Therapy), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Antibody-radionuclide Conjugates.
Regionally, the report analyzes the Antibody-radionuclide Conjugates markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Antibody-radionuclide Conjugates market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Antibody-radionuclide Conjugates market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Antibody-radionuclide Conjugates industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Beta-emitting, Targeted Alpha Therapy).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Antibody-radionuclide Conjugates market.
Regional Analysis: The report involves examining the Antibody-radionuclide Conjugates market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Antibody-radionuclide Conjugates market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Antibody-radionuclide Conjugates:
Company Analysis: Report covers individual Antibody-radionuclide Conjugates players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Antibody-radionuclide Conjugates This may involve surveys, interviews, and analysis of consumer reviews and feedback from different ?? (Solid Tumor, Non Hodgkin Lymphoma).
Technology Analysis: Report covers specific technologies relevant to Antibody-radionuclide Conjugates. It assesses the current state, advancements, and potential future developments in Antibody-radionuclide Conjugates areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Antibody-radionuclide Conjugates market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Antibody-radionuclide Conjugates market is split by Type and ??. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and ?? in terms of value.
Market segment by Type
- Beta-emitting
- Targeted Alpha Therapy
- Solid Tumor
- Non Hodgkin Lymphoma
- Bayer
- Novartis
- Lantheus
- Aurobindo Pharma
- Mundipharma
- China Isotope & Radiation
- Curium Pharmaceuticals
- Gilead Sciences
- Clarity Pharmaceuticals
- Curasight
- Nordic Nanovector
- Philogen
- RadioMedix
- Telix Pharmaceuticals
- Orano Med
- Actinium Pharmaceuticals
- Y-mAbs Therapeutics
- Fusion Pharmaceuticals
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Antibody-radionuclide Conjugates product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Antibody-radionuclide Conjugates, with revenue, gross margin and global market share of Antibody-radionuclide Conjugates from 2018 to 2023.
Chapter 3, the Antibody-radionuclide Conjugates competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Antibody-radionuclide Conjugates market forecast, by regions, type and , with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Antibody-radionuclide Conjugates.
Chapter 13, to describe Antibody-radionuclide Conjugates research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Antibody-radionuclide Conjugates
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Antibody-radionuclide Conjugates by Type
1.3.1 Overview: Global Antibody-radionuclide Conjugates Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Antibody-radionuclide Conjugates Consumption Value Market Share by Type in 2022
1.3.3 Beta-emitting
1.3.4 Targeted Alpha Therapy
1.4 Global Antibody-radionuclide Conjugates Market ??
1.4.1 Overview: Global Antibody-radionuclide Conjugates Market Size ??: 2018 Versus 2022 Versus 2029
1.4.2 Solid Tumor
1.4.3 Non Hodgkin Lymphoma
1.5 Global Antibody-radionuclide Conjugates Market Size & Forecast
1.6 Global Antibody-radionuclide Conjugates Market Size and Forecast by Region
1.6.1 Global Antibody-radionuclide Conjugates Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Antibody-radionuclide Conjugates Market Size by Region, (2018-2029)
1.6.3 North America Antibody-radionuclide Conjugates Market Size and Prospect (2018-2029)
1.6.4 Europe Antibody-radionuclide Conjugates Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Antibody-radionuclide Conjugates Market Size and Prospect (2018-2029)
1.6.6 South America Antibody-radionuclide Conjugates Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Antibody-radionuclide Conjugates Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Antibody-radionuclide Conjugates Product and Solutions
2.1.4 Bayer Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Bayer Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Antibody-radionuclide Conjugates Product and Solutions
2.2.4 Novartis Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Lantheus
2.3.1 Lantheus Details
2.3.2 Lantheus Major Business
2.3.3 Lantheus Antibody-radionuclide Conjugates Product and Solutions
2.3.4 Lantheus Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Lantheus Recent Developments and Future Plans
2.4 Aurobindo Pharma
2.4.1 Aurobindo Pharma Details
2.4.2 Aurobindo Pharma Major Business
2.4.3 Aurobindo Pharma Antibody-radionuclide Conjugates Product and Solutions
2.4.4 Aurobindo Pharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Aurobindo Pharma Recent Developments and Future Plans
2.5 Mundipharma
2.5.1 Mundipharma Details
2.5.2 Mundipharma Major Business
2.5.3 Mundipharma Antibody-radionuclide Conjugates Product and Solutions
2.5.4 Mundipharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Mundipharma Recent Developments and Future Plans
2.6 China Isotope & Radiation
2.6.1 China Isotope & Radiation Details
2.6.2 China Isotope & Radiation Major Business
2.6.3 China Isotope & Radiation Antibody-radionuclide Conjugates Product and Solutions
2.6.4 China Isotope & Radiation Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 China Isotope & Radiation Recent Developments and Future Plans
2.7 Curium Pharmaceuticals
2.7.1 Curium Pharmaceuticals Details
2.7.2 Curium Pharmaceuticals Major Business
2.7.3 Curium Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
2.7.4 Curium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Curium Pharmaceuticals Recent Developments and Future Plans
2.8 Gilead Sciences
2.8.1 Gilead Sciences Details
2.8.2 Gilead Sciences Major Business
2.8.3 Gilead Sciences Antibody-radionuclide Conjugates Product and Solutions
2.8.4 Gilead Sciences Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Gilead Sciences Recent Developments and Future Plans
2.9 Clarity Pharmaceuticals
2.9.1 Clarity Pharmaceuticals Details
2.9.2 Clarity Pharmaceuticals Major Business
2.9.3 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
2.9.4 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Clarity Pharmaceuticals Recent Developments and Future Plans
2.10 Curasight
2.10.1 Curasight Details
2.10.2 Curasight Major Business
2.10.3 Curasight Antibody-radionuclide Conjugates Product and Solutions
2.10.4 Curasight Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Curasight Recent Developments and Future Plans
2.11 Nordic Nanovector
2.11.1 Nordic Nanovector Details
2.11.2 Nordic Nanovector Major Business
2.11.3 Nordic Nanovector Antibody-radionuclide Conjugates Product and Solutions
2.11.4 Nordic Nanovector Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Nordic Nanovector Recent Developments and Future Plans
2.12 Philogen
2.12.1 Philogen Details
2.12.2 Philogen Major Business
2.12.3 Philogen Antibody-radionuclide Conjugates Product and Solutions
2.12.4 Philogen Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Philogen Recent Developments and Future Plans
2.13 RadioMedix
2.13.1 RadioMedix Details
2.13.2 RadioMedix Major Business
2.13.3 RadioMedix Antibody-radionuclide Conjugates Product and Solutions
2.13.4 RadioMedix Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 RadioMedix Recent Developments and Future Plans
2.14 Telix Pharmaceuticals
2.14.1 Telix Pharmaceuticals Details
2.14.2 Telix Pharmaceuticals Major Business
2.14.3 Telix Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
2.14.4 Telix Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Telix Pharmaceuticals Recent Developments and Future Plans
2.15 Orano Med
2.15.1 Orano Med Details
2.15.2 Orano Med Major Business
2.15.3 Orano Med Antibody-radionuclide Conjugates Product and Solutions
2.15.4 Orano Med Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Orano Med Recent Developments and Future Plans
2.16 Actinium Pharmaceuticals
2.16.1 Actinium Pharmaceuticals Details
2.16.2 Actinium Pharmaceuticals Major Business
2.16.3 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
2.16.4 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Actinium Pharmaceuticals Recent Developments and Future Plans
2.17 Y-mAbs Therapeutics
2.17.1 Y-mAbs Therapeutics Details
2.17.2 Y-mAbs Therapeutics Major Business
2.17.3 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product and Solutions
2.17.4 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Y-mAbs Therapeutics Recent Developments and Future Plans
2.18 Fusion Pharmaceuticals
2.18.1 Fusion Pharmaceuticals Details
2.18.2 Fusion Pharmaceuticals Major Business
2.18.3 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
2.18.4 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Fusion Pharmaceuticals Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Antibody-radionuclide Conjugates Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Antibody-radionuclide Conjugates by Company Revenue
3.2.2 Top 3 Antibody-radionuclide Conjugates Players Market Share in 2022
3.2.3 Top 6 Antibody-radionuclide Conjugates Players Market Share in 2022
3.3 Antibody-radionuclide Conjugates Market: Overall Company Footprint Analysis
3.3.1 Antibody-radionuclide Conjugates Market: Region Footprint
3.3.2 Antibody-radionuclide Conjugates Market: Company Product Type Footprint
3.3.3 Antibody-radionuclide Conjugates Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Antibody-radionuclide Conjugates Consumption Value and Market Share by Type (2018-2023)
4.2 Global Antibody-radionuclide Conjugates Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT ??
5.1 Global Antibody-radionuclide Conjugates Consumption Value Market Share ?? (2018-2023)
5.2 Global Antibody-radionuclide Conjugates Market Forecast ?? (2024-2029)
6 NORTH AMERICA
6.1 North America Antibody-radionuclide Conjugates Consumption Value by Type (2018-2029)
6.2 North America Antibody-radionuclide Conjugates Consumption Value ?? (2018-2029)
6.3 North America Antibody-radionuclide Conjugates Market Size by Country
6.3.1 North America Antibody-radionuclide Conjugates Consumption Value by Country (2018-2029)
6.3.2 United States Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
6.3.3 Canada Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
6.3.4 Mexico Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Antibody-radionuclide Conjugates Consumption Value by Type (2018-2029)
7.2 Europe Antibody-radionuclide Conjugates Consumption Value ?? (2018-2029)
7.3 Europe Antibody-radionuclide Conjugates Market Size by Country
7.3.1 Europe Antibody-radionuclide Conjugates Consumption Value by Country (2018-2029)
7.3.2 Germany Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
7.3.3 France Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
7.3.5 Russia Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
7.3.6 Italy Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Antibody-radionuclide Conjugates Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Antibody-radionuclide Conjugates Consumption Value ?? (2018-2029)
8.3 Asia-Pacific Antibody-radionuclide Conjugates Market Size by Region
8.3.1 Asia-Pacific Antibody-radionuclide Conjugates Consumption Value by Region (2018-2029)
8.3.2 China Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
8.3.3 Japan Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
8.3.4 South Korea Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
8.3.5 India Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
8.3.7 Australia Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Antibody-radionuclide Conjugates Consumption Value by Type (2018-2029)
9.2 South America Antibody-radionuclide Conjugates Consumption Value ?? (2018-2029)
9.3 South America Antibody-radionuclide Conjugates Market Size by Country
9.3.1 South America Antibody-radionuclide Conjugates Consumption Value by Country (2018-2029)
9.3.2 Brazil Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
9.3.3 Argentina Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Antibody-radionuclide Conjugates Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Antibody-radionuclide Conjugates Consumption Value ?? (2018-2029)
10.3 Middle East & Africa Antibody-radionuclide Conjugates Market Size by Country
10.3.1 Middle East & Africa Antibody-radionuclide Conjugates Consumption Value by Country (2018-2029)
10.3.2 Turkey Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
10.3.4 UAE Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Antibody-radionuclide Conjugates Market Drivers
11.2 Antibody-radionuclide Conjugates Market Restraints
11.3 Antibody-radionuclide Conjugates Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Antibody-radionuclide Conjugates Industry Chain
12.2 Antibody-radionuclide Conjugates Upstream Analysis
12.3 Antibody-radionuclide Conjugates Midstream Analysis
12.4 Antibody-radionuclide Conjugates Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Antibody-radionuclide Conjugates
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Antibody-radionuclide Conjugates by Type
1.3.1 Overview: Global Antibody-radionuclide Conjugates Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Antibody-radionuclide Conjugates Consumption Value Market Share by Type in 2022
1.3.3 Beta-emitting
1.3.4 Targeted Alpha Therapy
1.4 Global Antibody-radionuclide Conjugates Market ??
1.4.1 Overview: Global Antibody-radionuclide Conjugates Market Size ??: 2018 Versus 2022 Versus 2029
1.4.2 Solid Tumor
1.4.3 Non Hodgkin Lymphoma
1.5 Global Antibody-radionuclide Conjugates Market Size & Forecast
1.6 Global Antibody-radionuclide Conjugates Market Size and Forecast by Region
1.6.1 Global Antibody-radionuclide Conjugates Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Antibody-radionuclide Conjugates Market Size by Region, (2018-2029)
1.6.3 North America Antibody-radionuclide Conjugates Market Size and Prospect (2018-2029)
1.6.4 Europe Antibody-radionuclide Conjugates Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Antibody-radionuclide Conjugates Market Size and Prospect (2018-2029)
1.6.6 South America Antibody-radionuclide Conjugates Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Antibody-radionuclide Conjugates Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Antibody-radionuclide Conjugates Product and Solutions
2.1.4 Bayer Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Bayer Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Antibody-radionuclide Conjugates Product and Solutions
2.2.4 Novartis Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Lantheus
2.3.1 Lantheus Details
2.3.2 Lantheus Major Business
2.3.3 Lantheus Antibody-radionuclide Conjugates Product and Solutions
2.3.4 Lantheus Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Lantheus Recent Developments and Future Plans
2.4 Aurobindo Pharma
2.4.1 Aurobindo Pharma Details
2.4.2 Aurobindo Pharma Major Business
2.4.3 Aurobindo Pharma Antibody-radionuclide Conjugates Product and Solutions
2.4.4 Aurobindo Pharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Aurobindo Pharma Recent Developments and Future Plans
2.5 Mundipharma
2.5.1 Mundipharma Details
2.5.2 Mundipharma Major Business
2.5.3 Mundipharma Antibody-radionuclide Conjugates Product and Solutions
2.5.4 Mundipharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Mundipharma Recent Developments and Future Plans
2.6 China Isotope & Radiation
2.6.1 China Isotope & Radiation Details
2.6.2 China Isotope & Radiation Major Business
2.6.3 China Isotope & Radiation Antibody-radionuclide Conjugates Product and Solutions
2.6.4 China Isotope & Radiation Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 China Isotope & Radiation Recent Developments and Future Plans
2.7 Curium Pharmaceuticals
2.7.1 Curium Pharmaceuticals Details
2.7.2 Curium Pharmaceuticals Major Business
2.7.3 Curium Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
2.7.4 Curium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Curium Pharmaceuticals Recent Developments and Future Plans
2.8 Gilead Sciences
2.8.1 Gilead Sciences Details
2.8.2 Gilead Sciences Major Business
2.8.3 Gilead Sciences Antibody-radionuclide Conjugates Product and Solutions
2.8.4 Gilead Sciences Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Gilead Sciences Recent Developments and Future Plans
2.9 Clarity Pharmaceuticals
2.9.1 Clarity Pharmaceuticals Details
2.9.2 Clarity Pharmaceuticals Major Business
2.9.3 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
2.9.4 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Clarity Pharmaceuticals Recent Developments and Future Plans
2.10 Curasight
2.10.1 Curasight Details
2.10.2 Curasight Major Business
2.10.3 Curasight Antibody-radionuclide Conjugates Product and Solutions
2.10.4 Curasight Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Curasight Recent Developments and Future Plans
2.11 Nordic Nanovector
2.11.1 Nordic Nanovector Details
2.11.2 Nordic Nanovector Major Business
2.11.3 Nordic Nanovector Antibody-radionuclide Conjugates Product and Solutions
2.11.4 Nordic Nanovector Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Nordic Nanovector Recent Developments and Future Plans
2.12 Philogen
2.12.1 Philogen Details
2.12.2 Philogen Major Business
2.12.3 Philogen Antibody-radionuclide Conjugates Product and Solutions
2.12.4 Philogen Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Philogen Recent Developments and Future Plans
2.13 RadioMedix
2.13.1 RadioMedix Details
2.13.2 RadioMedix Major Business
2.13.3 RadioMedix Antibody-radionuclide Conjugates Product and Solutions
2.13.4 RadioMedix Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 RadioMedix Recent Developments and Future Plans
2.14 Telix Pharmaceuticals
2.14.1 Telix Pharmaceuticals Details
2.14.2 Telix Pharmaceuticals Major Business
2.14.3 Telix Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
2.14.4 Telix Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Telix Pharmaceuticals Recent Developments and Future Plans
2.15 Orano Med
2.15.1 Orano Med Details
2.15.2 Orano Med Major Business
2.15.3 Orano Med Antibody-radionuclide Conjugates Product and Solutions
2.15.4 Orano Med Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Orano Med Recent Developments and Future Plans
2.16 Actinium Pharmaceuticals
2.16.1 Actinium Pharmaceuticals Details
2.16.2 Actinium Pharmaceuticals Major Business
2.16.3 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
2.16.4 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Actinium Pharmaceuticals Recent Developments and Future Plans
2.17 Y-mAbs Therapeutics
2.17.1 Y-mAbs Therapeutics Details
2.17.2 Y-mAbs Therapeutics Major Business
2.17.3 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product and Solutions
2.17.4 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Y-mAbs Therapeutics Recent Developments and Future Plans
2.18 Fusion Pharmaceuticals
2.18.1 Fusion Pharmaceuticals Details
2.18.2 Fusion Pharmaceuticals Major Business
2.18.3 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
2.18.4 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Fusion Pharmaceuticals Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Antibody-radionuclide Conjugates Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Antibody-radionuclide Conjugates by Company Revenue
3.2.2 Top 3 Antibody-radionuclide Conjugates Players Market Share in 2022
3.2.3 Top 6 Antibody-radionuclide Conjugates Players Market Share in 2022
3.3 Antibody-radionuclide Conjugates Market: Overall Company Footprint Analysis
3.3.1 Antibody-radionuclide Conjugates Market: Region Footprint
3.3.2 Antibody-radionuclide Conjugates Market: Company Product Type Footprint
3.3.3 Antibody-radionuclide Conjugates Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Antibody-radionuclide Conjugates Consumption Value and Market Share by Type (2018-2023)
4.2 Global Antibody-radionuclide Conjugates Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT ??
5.1 Global Antibody-radionuclide Conjugates Consumption Value Market Share ?? (2018-2023)
5.2 Global Antibody-radionuclide Conjugates Market Forecast ?? (2024-2029)
6 NORTH AMERICA
6.1 North America Antibody-radionuclide Conjugates Consumption Value by Type (2018-2029)
6.2 North America Antibody-radionuclide Conjugates Consumption Value ?? (2018-2029)
6.3 North America Antibody-radionuclide Conjugates Market Size by Country
6.3.1 North America Antibody-radionuclide Conjugates Consumption Value by Country (2018-2029)
6.3.2 United States Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
6.3.3 Canada Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
6.3.4 Mexico Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Antibody-radionuclide Conjugates Consumption Value by Type (2018-2029)
7.2 Europe Antibody-radionuclide Conjugates Consumption Value ?? (2018-2029)
7.3 Europe Antibody-radionuclide Conjugates Market Size by Country
7.3.1 Europe Antibody-radionuclide Conjugates Consumption Value by Country (2018-2029)
7.3.2 Germany Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
7.3.3 France Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
7.3.5 Russia Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
7.3.6 Italy Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Antibody-radionuclide Conjugates Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Antibody-radionuclide Conjugates Consumption Value ?? (2018-2029)
8.3 Asia-Pacific Antibody-radionuclide Conjugates Market Size by Region
8.3.1 Asia-Pacific Antibody-radionuclide Conjugates Consumption Value by Region (2018-2029)
8.3.2 China Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
8.3.3 Japan Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
8.3.4 South Korea Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
8.3.5 India Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
8.3.7 Australia Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Antibody-radionuclide Conjugates Consumption Value by Type (2018-2029)
9.2 South America Antibody-radionuclide Conjugates Consumption Value ?? (2018-2029)
9.3 South America Antibody-radionuclide Conjugates Market Size by Country
9.3.1 South America Antibody-radionuclide Conjugates Consumption Value by Country (2018-2029)
9.3.2 Brazil Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
9.3.3 Argentina Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Antibody-radionuclide Conjugates Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Antibody-radionuclide Conjugates Consumption Value ?? (2018-2029)
10.3 Middle East & Africa Antibody-radionuclide Conjugates Market Size by Country
10.3.1 Middle East & Africa Antibody-radionuclide Conjugates Consumption Value by Country (2018-2029)
10.3.2 Turkey Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
10.3.4 UAE Antibody-radionuclide Conjugates Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Antibody-radionuclide Conjugates Market Drivers
11.2 Antibody-radionuclide Conjugates Market Restraints
11.3 Antibody-radionuclide Conjugates Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Antibody-radionuclide Conjugates Industry Chain
12.2 Antibody-radionuclide Conjugates Upstream Analysis
12.3 Antibody-radionuclide Conjugates Midstream Analysis
12.4 Antibody-radionuclide Conjugates Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Antibody-radionuclide Conjugates Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Antibody-radionuclide Conjugates Consumption Value ??, (USD Million), 2018 & 2022 & 2029
Table 3. Global Antibody-radionuclide Conjugates Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Antibody-radionuclide Conjugates Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Bayer Company Information, Head Office, and Major Competitors
Table 6. Bayer Major Business
Table 7. Bayer Antibody-radionuclide Conjugates Product and Solutions
Table 8. Bayer Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Bayer Recent Developments and Future Plans
Table 10. Novartis Company Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis Antibody-radionuclide Conjugates Product and Solutions
Table 13. Novartis Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Novartis Recent Developments and Future Plans
Table 15. Lantheus Company Information, Head Office, and Major Competitors
Table 16. Lantheus Major Business
Table 17. Lantheus Antibody-radionuclide Conjugates Product and Solutions
Table 18. Lantheus Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Lantheus Recent Developments and Future Plans
Table 20. Aurobindo Pharma Company Information, Head Office, and Major Competitors
Table 21. Aurobindo Pharma Major Business
Table 22. Aurobindo Pharma Antibody-radionuclide Conjugates Product and Solutions
Table 23. Aurobindo Pharma Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Aurobindo Pharma Recent Developments and Future Plans
Table 25. Mundipharma Company Information, Head Office, and Major Competitors
Table 26. Mundipharma Major Business
Table 27. Mundipharma Antibody-radionuclide Conjugates Product and Solutions
Table 28. Mundipharma Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Mundipharma Recent Developments and Future Plans
Table 30. China Isotope & Radiation Company Information, Head Office, and Major Competitors
Table 31. China Isotope & Radiation Major Business
Table 32. China Isotope & Radiation Antibody-radionuclide Conjugates Product and Solutions
Table 33. China Isotope & Radiation Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. China Isotope & Radiation Recent Developments and Future Plans
Table 35. Curium Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 36. Curium Pharmaceuticals Major Business
Table 37. Curium Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
Table 38. Curium Pharmaceuticals Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Curium Pharmaceuticals Recent Developments and Future Plans
Table 40. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 41. Gilead Sciences Major Business
Table 42. Gilead Sciences Antibody-radionuclide Conjugates Product and Solutions
Table 43. Gilead Sciences Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Gilead Sciences Recent Developments and Future Plans
Table 45. Clarity Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 46. Clarity Pharmaceuticals Major Business
Table 47. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
Table 48. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Clarity Pharmaceuticals Recent Developments and Future Plans
Table 50. Curasight Company Information, Head Office, and Major Competitors
Table 51. Curasight Major Business
Table 52. Curasight Antibody-radionuclide Conjugates Product and Solutions
Table 53. Curasight Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Curasight Recent Developments and Future Plans
Table 55. Nordic Nanovector Company Information, Head Office, and Major Competitors
Table 56. Nordic Nanovector Major Business
Table 57. Nordic Nanovector Antibody-radionuclide Conjugates Product and Solutions
Table 58. Nordic Nanovector Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Nordic Nanovector Recent Developments and Future Plans
Table 60. Philogen Company Information, Head Office, and Major Competitors
Table 61. Philogen Major Business
Table 62. Philogen Antibody-radionuclide Conjugates Product and Solutions
Table 63. Philogen Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Philogen Recent Developments and Future Plans
Table 65. RadioMedix Company Information, Head Office, and Major Competitors
Table 66. RadioMedix Major Business
Table 67. RadioMedix Antibody-radionuclide Conjugates Product and Solutions
Table 68. RadioMedix Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. RadioMedix Recent Developments and Future Plans
Table 70. Telix Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 71. Telix Pharmaceuticals Major Business
Table 72. Telix Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
Table 73. Telix Pharmaceuticals Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Telix Pharmaceuticals Recent Developments and Future Plans
Table 75. Orano Med Company Information, Head Office, and Major Competitors
Table 76. Orano Med Major Business
Table 77. Orano Med Antibody-radionuclide Conjugates Product and Solutions
Table 78. Orano Med Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Orano Med Recent Developments and Future Plans
Table 80. Actinium Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 81. Actinium Pharmaceuticals Major Business
Table 82. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
Table 83. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Actinium Pharmaceuticals Recent Developments and Future Plans
Table 85. Y-mAbs Therapeutics Company Information, Head Office, and Major Competitors
Table 86. Y-mAbs Therapeutics Major Business
Table 87. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product and Solutions
Table 88. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Y-mAbs Therapeutics Recent Developments and Future Plans
Table 90. Fusion Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 91. Fusion Pharmaceuticals Major Business
Table 92. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
Table 93. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Fusion Pharmaceuticals Recent Developments and Future Plans
Table 95. Global Antibody-radionuclide Conjugates Revenue (USD Million) by Players (2018-2023)
Table 96. Global Antibody-radionuclide Conjugates Revenue Share by Players (2018-2023)
Table 97. Breakdown of Antibody-radionuclide Conjugates by Company Type (Tier 1, Tier 2, and Tier 3)
Table 98. Market Position of Players in Antibody-radionuclide Conjugates, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 99. Head Office of Key Antibody-radionuclide Conjugates Players
Table 100. Antibody-radionuclide Conjugates Market: Company Product Type Footprint
Table 101. Antibody-radionuclide Conjugates Market: Company Product Application Footprint
Table 102. Antibody-radionuclide Conjugates New Market Entrants and Barriers to Market Entry
Table 103. Antibody-radionuclide Conjugates Mergers, Acquisition, Agreements, and Collaborations
Table 104. Global Antibody-radionuclide Conjugates Consumption Value (USD Million) by Type (2018-2023)
Table 105. Global Antibody-radionuclide Conjugates Consumption Value Share by Type (2018-2023)
Table 106. Global Antibody-radionuclide Conjugates Consumption Value Forecast by Type (2024-2029)
Table 107. Global Antibody-radionuclide Conjugates Consumption Value ?? (2018-2023)
Table 108. Global Antibody-radionuclide Conjugates Consumption Value Forecast ?? (2024-2029)
Table 109. North America Antibody-radionuclide Conjugates Consumption Value by Type (2018-2023) & (USD Million)
Table 110. North America Antibody-radionuclide Conjugates Consumption Value by Type (2024-2029) & (USD Million)
Table 111. North America Antibody-radionuclide Conjugates Consumption Value ?? (2018-2023) & (USD Million)
Table 112. North America Antibody-radionuclide Conjugates Consumption Value ?? (2024-2029) & (USD Million)
Table 113. North America Antibody-radionuclide Conjugates Consumption Value by Country (2018-2023) & (USD Million)
Table 114. North America Antibody-radionuclide Conjugates Consumption Value by Country (2024-2029) & (USD Million)
Table 115. Europe Antibody-radionuclide Conjugates Consumption Value by Type (2018-2023) & (USD Million)
Table 116. Europe Antibody-radionuclide Conjugates Consumption Value by Type (2024-2029) & (USD Million)
Table 117. Europe Antibody-radionuclide Conjugates Consumption Value ?? (2018-2023) & (USD Million)
Table 118. Europe Antibody-radionuclide Conjugates Consumption Value ?? (2024-2029) & (USD Million)
Table 119. Europe Antibody-radionuclide Conjugates Consumption Value by Country (2018-2023) & (USD Million)
Table 120. Europe Antibody-radionuclide Conjugates Consumption Value by Country (2024-2029) & (USD Million)
Table 121. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value by Type (2018-2023) & (USD Million)
Table 122. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value by Type (2024-2029) & (USD Million)
Table 123. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value ?? (2018-2023) & (USD Million)
Table 124. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value ?? (2024-2029) & (USD Million)
Table 125. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value by Region (2018-2023) & (USD Million)
Table 126. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value by Region (2024-2029) & (USD Million)
Table 127. South America Antibody-radionuclide Conjugates Consumption Value by Type (2018-2023) & (USD Million)
Table 128. South America Antibody-radionuclide Conjugates Consumption Value by Type (2024-2029) & (USD Million)
Table 129. South America Antibody-radionuclide Conjugates Consumption Value ?? (2018-2023) & (USD Million)
Table 130. South America Antibody-radionuclide Conjugates Consumption Value ?? (2024-2029) & (USD Million)
Table 131. South America Antibody-radionuclide Conjugates Consumption Value by Country (2018-2023) & (USD Million)
Table 132. South America Antibody-radionuclide Conjugates Consumption Value by Country (2024-2029) & (USD Million)
Table 133. Middle East & Africa Antibody-radionuclide Conjugates Consumption Value by Type (2018-2023) & (USD Million)
Table 134. Middle East & Africa Antibody-radionuclide Conjugates Consumption Value by Type (2024-2029) & (USD Million)
Table 135. Middle East & Africa Antibody-radionuclide Conjugates Consumption Value ?? (2018-2023) & (USD Million)
Table 136. Middle East & Africa Antibody-radionuclide Conjugates Consumption Value ?? (2024-2029) & (USD Million)
Table 137. Middle East & Africa Antibody-radionuclide Conjugates Consumption Value by Country (2018-2023) & (USD Million)
Table 138. Middle East & Africa Antibody-radionuclide Conjugates Consumption Value by Country (2024-2029) & (USD Million)
Table 139. Antibody-radionuclide Conjugates Raw Material
Table 140. Key Suppliers of Antibody-radionuclide Conjugates Raw Materials
LIST OF FIGURE
s
Figure 1. Antibody-radionuclide Conjugates Picture
Figure 2. Global Antibody-radionuclide Conjugates Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Antibody-radionuclide Conjugates Consumption Value Market Share by Type in 2022
Figure 4. Beta-emitting
Figure 5. Targeted Alpha Therapy
Figure 6. Global Antibody-radionuclide Conjugates Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Antibody-radionuclide Conjugates Consumption Value Market Share ?? in 2022
Figure 8. Solid Tumor Picture
Figure 9. Non Hodgkin Lymphoma Picture
Figure 10. Global Antibody-radionuclide Conjugates Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Antibody-radionuclide Conjugates Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Market Antibody-radionuclide Conjugates Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 13. Global Antibody-radionuclide Conjugates Consumption Value Market Share by Region (2018-2029)
Figure 14. Global Antibody-radionuclide Conjugates Consumption Value Market Share by Region in 2022
Figure 15. North America Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 16. Europe Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 17. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 18. South America Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 19. Middle East and Africa Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 20. Global Antibody-radionuclide Conjugates Revenue Share by Players in 2022
Figure 21. Antibody-radionuclide Conjugates Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 22. Global Top 3 Players Antibody-radionuclide Conjugates Market Share in 2022
Figure 23. Global Top 6 Players Antibody-radionuclide Conjugates Market Share in 2022
Figure 24. Global Antibody-radionuclide Conjugates Consumption Value Share by Type (2018-2023)
Figure 25. Global Antibody-radionuclide Conjugates Market Share Forecast by Type (2024-2029)
Figure 26. Global Antibody-radionuclide Conjugates Consumption Value Share ?? (2018-2023)
Figure 27. Global Antibody-radionuclide Conjugates Market Share Forecast ?? (2024-2029)
Figure 28. North America Antibody-radionuclide Conjugates Consumption Value Market Share by Type (2018-2029)
Figure 29. North America Antibody-radionuclide Conjugates Consumption Value Market Share ?? (2018-2029)
Figure 30. North America Antibody-radionuclide Conjugates Consumption Value Market Share by Country (2018-2029)
Figure 31. United States Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 32. Canada Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 33. Mexico Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 34. Europe Antibody-radionuclide Conjugates Consumption Value Market Share by Type (2018-2029)
Figure 35. Europe Antibody-radionuclide Conjugates Consumption Value Market Share ?? (2018-2029)
Figure 36. Europe Antibody-radionuclide Conjugates Consumption Value Market Share by Country (2018-2029)
Figure 37. Germany Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 38. France Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 39. United Kingdom Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 40. Russia Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 41. Italy Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 42. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value Market Share by Type (2018-2029)
Figure 43. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value Market Share ?? (2018-2029)
Figure 44. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value Market Share by Region (2018-2029)
Figure 45. China Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 46. Japan Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 47. South Korea Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 48. India Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 49. Southeast Asia Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 50. Australia Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 51. South America Antibody-radionuclide Conjugates Consumption Value Market Share by Type (2018-2029)
Figure 52. South America Antibody-radionuclide Conjugates Consumption Value Market Share ?? (2018-2029)
Figure 53. South America Antibody-radionuclide Conjugates Consumption Value Market Share by Country (2018-2029)
Figure 54. Brazil Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 55. Argentina Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 56. Middle East and Africa Antibody-radionuclide Conjugates Consumption Value Market Share by Type (2018-2029)
Figure 57. Middle East and Africa Antibody-radionuclide Conjugates Consumption Value Market Share ?? (2018-2029)
Figure 58. Middle East and Africa Antibody-radionuclide Conjugates Consumption Value Market Share by Country (2018-2029)
Figure 59. Turkey Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 60. Saudi Arabia Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 61. UAE Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 62. Antibody-radionuclide Conjugates Market Drivers
Figure 63. Antibody-radionuclide Conjugates Market Restraints
Figure 64. Antibody-radionuclide Conjugates Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of Antibody-radionuclide Conjugates in 2022
Figure 67. Manufacturing Process Analysis of Antibody-radionuclide Conjugates
Figure 68. Antibody-radionuclide Conjugates Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
Table 1. Global Antibody-radionuclide Conjugates Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Antibody-radionuclide Conjugates Consumption Value ??, (USD Million), 2018 & 2022 & 2029
Table 3. Global Antibody-radionuclide Conjugates Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Antibody-radionuclide Conjugates Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Bayer Company Information, Head Office, and Major Competitors
Table 6. Bayer Major Business
Table 7. Bayer Antibody-radionuclide Conjugates Product and Solutions
Table 8. Bayer Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Bayer Recent Developments and Future Plans
Table 10. Novartis Company Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis Antibody-radionuclide Conjugates Product and Solutions
Table 13. Novartis Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Novartis Recent Developments and Future Plans
Table 15. Lantheus Company Information, Head Office, and Major Competitors
Table 16. Lantheus Major Business
Table 17. Lantheus Antibody-radionuclide Conjugates Product and Solutions
Table 18. Lantheus Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Lantheus Recent Developments and Future Plans
Table 20. Aurobindo Pharma Company Information, Head Office, and Major Competitors
Table 21. Aurobindo Pharma Major Business
Table 22. Aurobindo Pharma Antibody-radionuclide Conjugates Product and Solutions
Table 23. Aurobindo Pharma Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Aurobindo Pharma Recent Developments and Future Plans
Table 25. Mundipharma Company Information, Head Office, and Major Competitors
Table 26. Mundipharma Major Business
Table 27. Mundipharma Antibody-radionuclide Conjugates Product and Solutions
Table 28. Mundipharma Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Mundipharma Recent Developments and Future Plans
Table 30. China Isotope & Radiation Company Information, Head Office, and Major Competitors
Table 31. China Isotope & Radiation Major Business
Table 32. China Isotope & Radiation Antibody-radionuclide Conjugates Product and Solutions
Table 33. China Isotope & Radiation Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. China Isotope & Radiation Recent Developments and Future Plans
Table 35. Curium Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 36. Curium Pharmaceuticals Major Business
Table 37. Curium Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
Table 38. Curium Pharmaceuticals Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Curium Pharmaceuticals Recent Developments and Future Plans
Table 40. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 41. Gilead Sciences Major Business
Table 42. Gilead Sciences Antibody-radionuclide Conjugates Product and Solutions
Table 43. Gilead Sciences Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Gilead Sciences Recent Developments and Future Plans
Table 45. Clarity Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 46. Clarity Pharmaceuticals Major Business
Table 47. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
Table 48. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Clarity Pharmaceuticals Recent Developments and Future Plans
Table 50. Curasight Company Information, Head Office, and Major Competitors
Table 51. Curasight Major Business
Table 52. Curasight Antibody-radionuclide Conjugates Product and Solutions
Table 53. Curasight Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Curasight Recent Developments and Future Plans
Table 55. Nordic Nanovector Company Information, Head Office, and Major Competitors
Table 56. Nordic Nanovector Major Business
Table 57. Nordic Nanovector Antibody-radionuclide Conjugates Product and Solutions
Table 58. Nordic Nanovector Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Nordic Nanovector Recent Developments and Future Plans
Table 60. Philogen Company Information, Head Office, and Major Competitors
Table 61. Philogen Major Business
Table 62. Philogen Antibody-radionuclide Conjugates Product and Solutions
Table 63. Philogen Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Philogen Recent Developments and Future Plans
Table 65. RadioMedix Company Information, Head Office, and Major Competitors
Table 66. RadioMedix Major Business
Table 67. RadioMedix Antibody-radionuclide Conjugates Product and Solutions
Table 68. RadioMedix Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. RadioMedix Recent Developments and Future Plans
Table 70. Telix Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 71. Telix Pharmaceuticals Major Business
Table 72. Telix Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
Table 73. Telix Pharmaceuticals Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Telix Pharmaceuticals Recent Developments and Future Plans
Table 75. Orano Med Company Information, Head Office, and Major Competitors
Table 76. Orano Med Major Business
Table 77. Orano Med Antibody-radionuclide Conjugates Product and Solutions
Table 78. Orano Med Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Orano Med Recent Developments and Future Plans
Table 80. Actinium Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 81. Actinium Pharmaceuticals Major Business
Table 82. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
Table 83. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Actinium Pharmaceuticals Recent Developments and Future Plans
Table 85. Y-mAbs Therapeutics Company Information, Head Office, and Major Competitors
Table 86. Y-mAbs Therapeutics Major Business
Table 87. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product and Solutions
Table 88. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Y-mAbs Therapeutics Recent Developments and Future Plans
Table 90. Fusion Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 91. Fusion Pharmaceuticals Major Business
Table 92. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product and Solutions
Table 93. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Fusion Pharmaceuticals Recent Developments and Future Plans
Table 95. Global Antibody-radionuclide Conjugates Revenue (USD Million) by Players (2018-2023)
Table 96. Global Antibody-radionuclide Conjugates Revenue Share by Players (2018-2023)
Table 97. Breakdown of Antibody-radionuclide Conjugates by Company Type (Tier 1, Tier 2, and Tier 3)
Table 98. Market Position of Players in Antibody-radionuclide Conjugates, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 99. Head Office of Key Antibody-radionuclide Conjugates Players
Table 100. Antibody-radionuclide Conjugates Market: Company Product Type Footprint
Table 101. Antibody-radionuclide Conjugates Market: Company Product Application Footprint
Table 102. Antibody-radionuclide Conjugates New Market Entrants and Barriers to Market Entry
Table 103. Antibody-radionuclide Conjugates Mergers, Acquisition, Agreements, and Collaborations
Table 104. Global Antibody-radionuclide Conjugates Consumption Value (USD Million) by Type (2018-2023)
Table 105. Global Antibody-radionuclide Conjugates Consumption Value Share by Type (2018-2023)
Table 106. Global Antibody-radionuclide Conjugates Consumption Value Forecast by Type (2024-2029)
Table 107. Global Antibody-radionuclide Conjugates Consumption Value ?? (2018-2023)
Table 108. Global Antibody-radionuclide Conjugates Consumption Value Forecast ?? (2024-2029)
Table 109. North America Antibody-radionuclide Conjugates Consumption Value by Type (2018-2023) & (USD Million)
Table 110. North America Antibody-radionuclide Conjugates Consumption Value by Type (2024-2029) & (USD Million)
Table 111. North America Antibody-radionuclide Conjugates Consumption Value ?? (2018-2023) & (USD Million)
Table 112. North America Antibody-radionuclide Conjugates Consumption Value ?? (2024-2029) & (USD Million)
Table 113. North America Antibody-radionuclide Conjugates Consumption Value by Country (2018-2023) & (USD Million)
Table 114. North America Antibody-radionuclide Conjugates Consumption Value by Country (2024-2029) & (USD Million)
Table 115. Europe Antibody-radionuclide Conjugates Consumption Value by Type (2018-2023) & (USD Million)
Table 116. Europe Antibody-radionuclide Conjugates Consumption Value by Type (2024-2029) & (USD Million)
Table 117. Europe Antibody-radionuclide Conjugates Consumption Value ?? (2018-2023) & (USD Million)
Table 118. Europe Antibody-radionuclide Conjugates Consumption Value ?? (2024-2029) & (USD Million)
Table 119. Europe Antibody-radionuclide Conjugates Consumption Value by Country (2018-2023) & (USD Million)
Table 120. Europe Antibody-radionuclide Conjugates Consumption Value by Country (2024-2029) & (USD Million)
Table 121. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value by Type (2018-2023) & (USD Million)
Table 122. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value by Type (2024-2029) & (USD Million)
Table 123. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value ?? (2018-2023) & (USD Million)
Table 124. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value ?? (2024-2029) & (USD Million)
Table 125. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value by Region (2018-2023) & (USD Million)
Table 126. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value by Region (2024-2029) & (USD Million)
Table 127. South America Antibody-radionuclide Conjugates Consumption Value by Type (2018-2023) & (USD Million)
Table 128. South America Antibody-radionuclide Conjugates Consumption Value by Type (2024-2029) & (USD Million)
Table 129. South America Antibody-radionuclide Conjugates Consumption Value ?? (2018-2023) & (USD Million)
Table 130. South America Antibody-radionuclide Conjugates Consumption Value ?? (2024-2029) & (USD Million)
Table 131. South America Antibody-radionuclide Conjugates Consumption Value by Country (2018-2023) & (USD Million)
Table 132. South America Antibody-radionuclide Conjugates Consumption Value by Country (2024-2029) & (USD Million)
Table 133. Middle East & Africa Antibody-radionuclide Conjugates Consumption Value by Type (2018-2023) & (USD Million)
Table 134. Middle East & Africa Antibody-radionuclide Conjugates Consumption Value by Type (2024-2029) & (USD Million)
Table 135. Middle East & Africa Antibody-radionuclide Conjugates Consumption Value ?? (2018-2023) & (USD Million)
Table 136. Middle East & Africa Antibody-radionuclide Conjugates Consumption Value ?? (2024-2029) & (USD Million)
Table 137. Middle East & Africa Antibody-radionuclide Conjugates Consumption Value by Country (2018-2023) & (USD Million)
Table 138. Middle East & Africa Antibody-radionuclide Conjugates Consumption Value by Country (2024-2029) & (USD Million)
Table 139. Antibody-radionuclide Conjugates Raw Material
Table 140. Key Suppliers of Antibody-radionuclide Conjugates Raw Materials
LIST OF FIGURE
s
Figure 1. Antibody-radionuclide Conjugates Picture
Figure 2. Global Antibody-radionuclide Conjugates Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Antibody-radionuclide Conjugates Consumption Value Market Share by Type in 2022
Figure 4. Beta-emitting
Figure 5. Targeted Alpha Therapy
Figure 6. Global Antibody-radionuclide Conjugates Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Antibody-radionuclide Conjugates Consumption Value Market Share ?? in 2022
Figure 8. Solid Tumor Picture
Figure 9. Non Hodgkin Lymphoma Picture
Figure 10. Global Antibody-radionuclide Conjugates Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Antibody-radionuclide Conjugates Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Market Antibody-radionuclide Conjugates Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 13. Global Antibody-radionuclide Conjugates Consumption Value Market Share by Region (2018-2029)
Figure 14. Global Antibody-radionuclide Conjugates Consumption Value Market Share by Region in 2022
Figure 15. North America Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 16. Europe Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 17. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 18. South America Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 19. Middle East and Africa Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 20. Global Antibody-radionuclide Conjugates Revenue Share by Players in 2022
Figure 21. Antibody-radionuclide Conjugates Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 22. Global Top 3 Players Antibody-radionuclide Conjugates Market Share in 2022
Figure 23. Global Top 6 Players Antibody-radionuclide Conjugates Market Share in 2022
Figure 24. Global Antibody-radionuclide Conjugates Consumption Value Share by Type (2018-2023)
Figure 25. Global Antibody-radionuclide Conjugates Market Share Forecast by Type (2024-2029)
Figure 26. Global Antibody-radionuclide Conjugates Consumption Value Share ?? (2018-2023)
Figure 27. Global Antibody-radionuclide Conjugates Market Share Forecast ?? (2024-2029)
Figure 28. North America Antibody-radionuclide Conjugates Consumption Value Market Share by Type (2018-2029)
Figure 29. North America Antibody-radionuclide Conjugates Consumption Value Market Share ?? (2018-2029)
Figure 30. North America Antibody-radionuclide Conjugates Consumption Value Market Share by Country (2018-2029)
Figure 31. United States Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 32. Canada Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 33. Mexico Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 34. Europe Antibody-radionuclide Conjugates Consumption Value Market Share by Type (2018-2029)
Figure 35. Europe Antibody-radionuclide Conjugates Consumption Value Market Share ?? (2018-2029)
Figure 36. Europe Antibody-radionuclide Conjugates Consumption Value Market Share by Country (2018-2029)
Figure 37. Germany Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 38. France Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 39. United Kingdom Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 40. Russia Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 41. Italy Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 42. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value Market Share by Type (2018-2029)
Figure 43. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value Market Share ?? (2018-2029)
Figure 44. Asia-Pacific Antibody-radionuclide Conjugates Consumption Value Market Share by Region (2018-2029)
Figure 45. China Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 46. Japan Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 47. South Korea Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 48. India Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 49. Southeast Asia Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 50. Australia Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 51. South America Antibody-radionuclide Conjugates Consumption Value Market Share by Type (2018-2029)
Figure 52. South America Antibody-radionuclide Conjugates Consumption Value Market Share ?? (2018-2029)
Figure 53. South America Antibody-radionuclide Conjugates Consumption Value Market Share by Country (2018-2029)
Figure 54. Brazil Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 55. Argentina Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 56. Middle East and Africa Antibody-radionuclide Conjugates Consumption Value Market Share by Type (2018-2029)
Figure 57. Middle East and Africa Antibody-radionuclide Conjugates Consumption Value Market Share ?? (2018-2029)
Figure 58. Middle East and Africa Antibody-radionuclide Conjugates Consumption Value Market Share by Country (2018-2029)
Figure 59. Turkey Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 60. Saudi Arabia Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 61. UAE Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 62. Antibody-radionuclide Conjugates Market Drivers
Figure 63. Antibody-radionuclide Conjugates Market Restraints
Figure 64. Antibody-radionuclide Conjugates Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of Antibody-radionuclide Conjugates in 2022
Figure 67. Manufacturing Process Analysis of Antibody-radionuclide Conjugates
Figure 68. Antibody-radionuclide Conjugates Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
